Published in J Pharm Sci on March 01, 2008
Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol (2012) 2.65
Materials engineering for immunomodulation. Nature (2009) 2.18
Engineering nano- and microparticles to tune immunity. Adv Mater (2012) 1.75
The use of self-adjuvanting nanofiber vaccines to elicit high-affinity B cell responses to peptide antigens without inflammation. Biomaterials (2013) 0.94
The Brucella abortus S19 DeltavjbR live vaccine candidate is safer than S19 and confers protection against wild-type challenge in BALB/c mice when delivered in a sustained-release vehicle. Infect Immun (2008) 0.93
Multifunctional dendritic cell-targeting polymeric microparticles: engineering new vaccines for type 1 diabetes. Hum Vaccin (2011) 0.89
Beyond antigens and adjuvants: formulating future vaccines. J Clin Invest (2016) 0.87
Application of nanotechnologies for improved immune response against infectious diseases in the developing world. Adv Drug Deliv Rev (2009) 0.84
Respiratory nanoparticle-based vaccines and challenges associated with animal models and translation. J Control Release (2015) 0.77
A therapeutic nanoparticle vaccine against Trypanosoma cruzi in a BALB/c mouse model of Chagas disease. Hum Vaccin Immunother (2016) 0.76
Mucosally delivered peptides prime strong immunity in HLA-A2.1 transgenic rabbits. Vaccine (2010) 0.76
Oral delivery of Brucella spp. recombinant protein U-Omp16 abrogates the IgE-mediated milk allergy. Hum Vaccin Immunother (2014) 0.76
Treatment of Mycobacterium tuberculosis-Infected Macrophages with Poly(Lactic-Co-Glycolic Acid) Microparticles Drives NFκB and Autophagy Dependent Bacillary Killing. PLoS One (2016) 0.75
Comparative analysis of routes of immunization of a live porcine reproductive and respiratory syndrome virus (PRRSV) vaccine in a heterologous virus challenge study. Vet Res (2016) 0.75
Peptide/protein vaccine delivery system based on PLGA particles. Hum Vaccin Immunother (2016) 0.75
TEMPORARY REMOVAL: Synthetic nanovaccines for immunotherapy. J Control Release (2017) 0.75
IL-21 is pivotal in determining age-dependent effectiveness of immune responses in a mouse model of human hepatitis B. J Clin Invest (2011) 3.59
Analysis of changing paradigms of management in 179 patients with spinal tuberculosis over a 12-year period and proposal of a new management algorithm. World Neurosurg (2013) 2.94
Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A (2012) 2.59
Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine (2011) 2.53
Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci U S A (2009) 2.42
Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS (2008) 2.06
Age-dependent hepatic lymphoid organization directs successful immunity to hepatitis B. J Clin Invest (2013) 2.04
The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J Immunol (2008) 1.71
An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J Virol (2003) 1.56
Association of interleukin-4 and interleukin-1 receptor antagonist gene polymorphisms and risk of benign prostatic hyperplasia. Urology (2008) 1.54
Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Colloids Surf B Biointerfaces (2009) 1.47
Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proc Natl Acad Sci U S A (2011) 1.44
The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury. Trials (2009) 1.43
Comparative analysis of diagnostic accuracy of different brain biopsy procedures. Neurol India (2006) 1.43
Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J (2009) 1.36
Mouse and human lung fibroblasts regulate dendritic cell trafficking, airway inflammation, and fibrosis through integrin αvβ8-mediated activation of TGF-β. J Clin Invest (2011) 1.25
Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine (2007) 1.24
Recent advances in vaccine adjuvants. Pharm Res (2002) 1.22
CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine. Infect Immun (2005) 1.16
MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020). Pharm Res (2009) 1.14
Endotoxin limits in formulations for preclinical research. J Pharm Sci (2008) 1.12
Recent advances in veterinary vaccine adjuvants. Int J Parasitol (2003) 1.11
Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency. J Control Release (2005) 1.07
Protection of rhesus monkeys by a DNA prime/poxvirus boost malaria vaccine depends on optimal DNA priming and inclusion of blood stage antigens. PLoS One (2007) 1.06
Microparticle-based technologies for vaccines. Methods (2006) 1.05
Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations. AIDS Res Hum Retroviruses (2004) 1.04
Microparticles for the delivery of DNA vaccines. Immunol Rev (2004) 1.04
Phase-sensitive optical coherence elastography at 1.5 million A-Lines per second. Opt Lett (2015) 1.04
Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines. Immunol Cell Biol (2004) 1.02
Quantitative methods for reconstructing tissue biomechanical properties in optical coherence elastography: a comparison study. Phys Med Biol (2015) 1.00
Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins. J Virol (2005) 1.00
Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys. Vaccine (2011) 1.00
Characterization of human immunodeficiency virus Gag-specific gamma interferon-expressing cells following protective mucosal immunization with alphavirus replicon particles. J Virol (2005) 1.00
The long-term potential of biodegradable poly(lactide-co-glycolide) microparticles as the next-generation vaccine adjuvant. Expert Rev Vaccines (2011) 0.98
A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens. Vaccine (2005) 0.97
Spontaneous rupture of hydrocephalic head. Neurol India (2013) 0.96
All that palsies is not Bell's -the need to define Bell's palsy as an adverse event following immunization. Vaccine (2007) 0.95
Enhancing the therapeutic efficacy of CpG oligonucleotides using biodegradable microparticles. Adv Drug Deliv Rev (2009) 0.95
The vaccine adjuvant alum inhibits IL-12 by promoting PI3 kinase signaling while chitosan does not inhibit IL-12 and enhances Th1 and Th17 responses. Eur J Immunol (2012) 0.95
Acceptable levels of endotoxin in vaccine formulations during preclinical research. J Pharm Sci (2011) 0.94
Enhanced mucosal and systemic immune responses to Helicobacter pylori antigens through mucosal priming followed by systemic boosting immunizations. Immunology (2003) 0.94
Microparticles as vaccine adjuvants and delivery systems. Expert Rev Vaccines (2003) 0.94
Spinal teratomas: a clinico-pathological study of 27 patients. Acta Neurochir (Wien) (2009) 0.93
Prognostic value of MIB-1, p53, epidermal growth factor receptor, and INI1 in childhood chordomas. Neuro Oncol (2013) 0.92
Dynamic optical coherence tomography measurements of elastic wave propagation in tissue-mimicking phantoms and mouse cornea in vivo. J Biomed Opt (2013) 0.92
Dissolvable microneedle patches for the delivery of cell-culture-derived influenza vaccine antigens. J Pharm Sci (2011) 0.92
Helicobacter pylori lipopolysaccharide promotes a Th1 type immune response in immunized mice. Vaccine (2006) 0.91
Effects of a Th1- versus a Th2-biased immune response in protection against Helicobacter pylori challenge in mice. Microb Pathog (2007) 0.90
Antibody responses against HIV in rhesus macaques following combinations of mucosal and systemic immunizations with chimeric alphavirus-based replicon particles. AIDS Res Hum Retroviruses (2006) 0.90
Polylactide-co-glycolide microparticles with surface adsorbed antigens as vaccine delivery systems. Curr Drug Deliv (2006) 0.90
Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses. J Gen Virol (2006) 0.90
Mechanisms of increased immunogenicity for DNA-based vaccines adsorbed onto cationic microparticles. Cell Immunol (2003) 0.90
A comparison of anionic nanoparticles and microparticles as vaccine delivery systems. Hum Vaccin (2007) 0.89
Dynamics of acute and memory mucosal and systemic immune responses against HIV-1 envelope following immunizations through single or combinations of mucosal and systemic routes. Vaccine (2007) 0.89
A practical approach to the use of nanoparticles for vaccine delivery. J Pharm Sci (2006) 0.88
Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B. J Pharm Sci (2004) 0.87